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Background/aim: Peritonitis attacks of Familial Mediterranean Fever (FMF) usually requires emergency medical admissions and
it’s hard to distinguish a typical abdominal attack from surgical causes of acute abdomen. Therefore, history of abdominal surgery,
particularly appendectomy, is very common in patients with FMF. However, history of appendectomy might also give some clues about
the course of FMF in the adulthood. This study was to determine whether the history of appendectomy help to anticipate disease course
of FMF in the adulthood.
Materials and methods: All patients recruited from FMF in Central Anatolia (FiCA) cohort, comprising 971 adult subjects. All patients
fulfilled the Tel Hashomer criteria. Demographic data, FMF disease characteristics, co-morbid conditions, past medical history, surgical
history and disease complications were meticulously questioned and laboratory features and genotype data (if available) were recruited
from patient files.
Results: Appendectomy history was evident in 240 (24.7%) subjects. Disease onset was earlier and peritonitis is strikingly more prevalent
(97.1% vs. 89.6%, p < 0.001) in appendectomized patients. These patients had reported almost two fold more frequent attacks in the last
year compared to appendix intact patients (median 3.5 vs. 2 attacks, p = 0.001) without a difference in frequency of musculoskeletal and
skin attacks. Severe disease was more common (10% vs. 5.9%, p = 0.038) due to involvement of more attack sites throughout the life and
more frequent attacks. Appendectomy patients had used higher daily doses of colchicine to control disease (1.43 ± 0.6 mg vs. 1.27 ± 0.52
mg, p = 0.002) but colchicine resistance was also more common in these patients, 15% vs. 6.7% respectively, p < 0.001.
Conclusion: Appendectomy history is common in FMF patients and associated with frequent serositis attacks in adulthood. These
patients require higher colchicine doses with a lower rate of response and more need for Interleukin-1 antagonist therapies.
Key words: Familial Mediterranean fever, appendectomy, surgery, prognosis, colchicine resistance

1. Introduction
Familial Mediterranean fever (FMF) is the most common
hereditary autoinflammatory disorder characterized by
recurrent attacks of fever, peritonitis, pleuritis, synovitis,
and erysipelas-like erythema [1,2]. It frequently occurs
among Turks, Armenians, Jews, and Arabs, but several
hundreds of patients described in non-Mediterranean
countries [3]. Disease onset is prior to 10 years of age in
60% of cases and before age 20 in 90% of cases, although
disease may start at any age [4]. Typical FMF attacks are
self-limited and last between 1 to 3 days without a sequela.
There is no diagnostic laboratory marker and genetic

analysis by itself has low sensitivity and specificity; hence,
the diagnosis of FMF relies mainly on clinical criteria [5].
Due to rarity of disease and lack of specific diagnostic tests
most cases of FMF remain undiagnosed or misdiagnosed
[6].
The most common manifestation of FMF is episodic
abdominal pain resulting from sterile peritonitis which
occur 95 percent of the patients [4]. Abdominal pain and
tenderness usually start as localized and then progress to
become more generalized. Since the cause of abdominal
pain is the inflammation of the peritoneum, signs of
peritonitis such as guarding, rebound tenderness, rigidity,
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and adynamic ileus are often present, a clinical emergency
scenario quite similar to “acute surgical abdomen”. The most
common cause of acute surgical abdomen in childhood is
acute appendicitis with a peak incidence between 10–19
years. The lifetime risk of acute appendicitis is 7%–9%,
which is far beyond the prevalence of FMF [7] which has a
prevalence of 1/400–1/1000 in endemic countries [8].
In clinical practice, appendicitis, ileus/subileus,
cholecystitis, and renal colic may be perceived as causes
of abdominal pain before a reliable diagnosis of FMF
has been made, which may lead to misdiagnosis and
inappropriate treatments [9]. Heterogeneity of FMF
attacks, in terms of severity and duration, and their erratic
recurrence and remission, together with the rare incidence
and low awareness, explain diagnostic delays of these
disorders and the high rate of unnecessary laparotomies
and appendectomies [9]. Therefore, routine preoperative
screening for a personal or family history of symptoms
compatible with FMF, should undoubtedly reduce the
frequency of unwarranted surgical interventions.
In patients with FMF, appendectomy is usually
performed in childhood prior to the diagnosis, however
even confirmation of FMF diagnosis, some patients
underwent laparotomy due to difficulties in distinguishing
FMF peritonitis from acute surgical abdomen causes. In
previous reports abdominal surgery history rate is as high
as 20% in FMF patients [10]. Our observation is that,
patients with history of appendectomy or laparotomy
experience more attacks than those who did not have these
operations which may give a clue about the clinical course
of FMF in adulthood. Herein, we aimed to investigate
clinical features and disease course of FMF patients with
history of appendectomy in a large cohort.
2. Materials and methods
In this study, we enrolled 971 adult patients with FMF who
followed at the outpatient rheumatology clinics of three
university hospitals: Gazi University, Hacettepe University,
and Eskişehir Osmangazi University Hospitals which
admit patients from all over the country. The study was
conducted between January 2018 and December 2018. The
diagnosis of FMF was made according to the Tel Hashomer
criteria [11]. This study was approved by Gazi University
ethical committee (approval no. 2017-622), conducted in
accordance with the 1975 Helsinki Declaration. Informed
consent was obtained from all participants before the
inclusion of study.
Demographic data, FMF disease characteristics,
co-morbid conditions, past medical history including
surgeries, medication history, colchicine doses, and
disease complications were meticulously questioned
and laboratory features were recruited from patient
files. Disease severity and FMF associated damage were

assessed with International Severity Scoring System for
FMF (ISSF) and Autoinflammatory Disease Damage Index
(ADDI), respectively [12,13]. Having less than one attack
per 6-months-period is defined as complete response to
colchicine. Colchicine resistance (crFMF) was defined as
experiencing more than one attack per month despite the
maximal tolerated dose of colchicine [14].
In ADDI, damage is defined as “persistent or
irreversible change in structure or function, that is present
for more than 6 months” [12]. ADDI contains 18 items,
and these items are categorized by organ systems as
follows: reproductive, renal/amyloidosis, developmental,
serosal, neurological, ears, ocular, and musculoskeletal.
The renal/amyloidosis and neurological damage categories
were assigned to have the highest number of points
while serosal damage got the lowest. This index provides
a universal instrument to measure damage by chronic
inflammation in FMF [15].
ISSF was developed to measure disease severity in
children and adult FMF patients for research purposes and
clinical practice. It consists of nine clinical and laboratory
variables: chronic sequela, organ dysfunction, organ
failure, attack frequency, increased acute-phase reactants,
involvement of more than two sites during a single episode,
more than two different types of attack during the course
of the disease, duration of attacks, and exertional leg pain
[13]. The maximum score is 10 and the degree of severity
was determined as mild (≤2), intermediate (3–5) or severe
disease (≥6) [12].
For statistical analyzes, patients were divided into two
groups according to their history of appendectomy as
Appendectomy Performed (AP) or Appendix Intact (AI).
Differences between attack features, disease severities,
damage accrual and treatment responses were compared.
Categorical variables were given as numbers and
percentages, and continuous variables were presented with
their mean ± standard deviation (SD) or median (25%–
75% interquartile ranges) for descriptive analysis. The
conformity of continuous variables to normal distribution
was evaluated by using visual (histogram and probability
graphs) and analytical methods (Kolmogorov–Smirnov/
Shapiro–Wilk tests). If variables were normally distributed
Student-t-test was used, if not Mann–Whitney U test was
used for comparison of data sets. The chi-square test was
used for the comparison of categorical variables. p < 0.05
was considered as statistically significant in all analyzes.
3. Results
The study comprised of 971 FMF patients (597 female,
mean age 35.3 ± 12.1 years). Appendectomy history was
evident in 240 (24.7%) subjects. AP group is a bit older
and had an earlier disease onset (Table 1). In AP group
mutation negative patients were less and those with two
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Table 1. Demographic, clinical, and attack features of patients Familial Mediterranean fever.
Appendectomy performed (AP)
group (n = 240)

Appendix intact (AI)
group (n = 731)

p

Age, years*

37.2 ± 11.8

34.6 ± 12.1

0.004

Female

151 (62.9)

446 (61.0)

Male

89 (37.1)

285 (38.9)

FMF onset ≤10 years old

137 (57.1)

357 (48.8)

0.027

Age at FMF diagnosis, years*

0.7

0.6

24.8 ± 12.9

24.4±13.2

Mutation negative

14 (5.8)

60 (8.2)

Single mutation

58 (24.2)

256 (35.0)

Double mutation

118 (49.2)

308 (42.2)

Mutation unknown

50 (20.8)

107 (14.6)

0.28

Harboring M694V mutation

150 (65.5)

469 (64.2)

0.15

M694V homozygous

60 (25)

165 (21.7)

0.17

Fever

206 (85.8)

601 (82.2)

0.22

Peritonitis

233 (97.1)

655 (89.6)

<0.001

Pleuritis

120 (50)

345 (47.2)

0.43

Arthritis

117 (48.7)

303 (41.4)

0.043

Erysipelas like erythema

78 (32.5)

176 (24.1)

0.009

Myalgia

64 (26.7)

151 (20.6)

0.053

Family history of amyloidosis

14 (6.2)**

31 (5.3)***

0.6

Disease severity (ISSF score)*

3.13 ± 1.67

2.73 ± 1.48

0.001

Mild disease

102 (42.5)

361 (49.4)

Intermediate disease

114 (47.5)

327 (44.7)

Severe disease

24 (10)

43 (5.9)

Number of
mutations

ISSF

0.009

0.038

All data are presented as number (%), or *mean ± standard deviation. Data available for **226 and ***587 patients, respectively. FMF:
familial Mediterranean fever, ISSF: International Severity Scoring System.

mutations were more common, without a difference
in M694V homozygous mutation. Considering types
of attacks evaluated as ever experienced till inclusion,
peritonitis is strikingly more prevalent in AP group (97.1%
vs. 89.6%, p < 0.001). Arthritis, skin rash and myositis were
also more common in AP group compared to AI group
(Table 1).
AP group had reported almost twice as many attacks
compared to AI group, in the last year (median 3.5 vs. 2
attack, p = 0.001), of the study inclusion. When attacks
were individually analyzed, there were differences in the
frequency of fever, peritonitis and pleuritis attacks in the
last year (Table 2). However, there was no difference in the
frequency of musculoskeletal and skin attacks between
AP and AI groups. Severe disease, assessed with ISSF, is
more common in AP group (10% vs. 5.9%, p = 0.038) due
to involvement of more disease sites and more frequent
attacks.
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AP group had used higher doses of colchicine to
control their disease (1.43 ± 0.6 mg vs. 1.27 ± 0.52 mg,
p = 0.002). Colchicine resistance was also more prevalent
in AP group, 15% vs. 6.7% respectively, p < 0.001. The
proportion of patients in AP group is higher for antiIL-1 antagonist (anakinra or canakinumab) use. History
of other abdominal surgeries such as, cholecystectomy or
gynecologic operations were also more common in AP
group (median total number of abdominal surgery 2 vs.
0 in AP and AI groups respectively, <0.001). Although
severe disease was more common in AP group, no
difference in FMF associated complications was observed,
such as prevalence of chronic inflammation, amyloidosis
and damage accrual.
4. Discussion
Results of this study shows that appendectomy history is
extremely common in FMF patients. Moreover, patients
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Table 2. Disease course and prognostic parameters of Familial Mediterranean fever patient groups in the last year before enrollment.
Appendectomy performed (AP)
group/median (n = 240)

Appendix intact (AI)
group/median (n = 731)

p

3.5 (0–10)

2 (0–5)

0.001

Fever

2 (0–5)

1 (0–3)

0.005

Peritonitis

2 (0–6)

1 (0–4)

0.014

Pleuritis

2.5 (0–5)

1 (0–4)

0.03

Arthritis

1 (0–4)

1 (0–3)

0.4

ELE

0 (0–3)

0 (0–2)

0.9

Myalgia

Number of all type of attacks in the last year

3 (0–10)

2 (0–5)

0.1

Colchicine dose in the last visit, mg*

1.43 ± 0.60

1.27 ± 0.52

0.002

Colchicine nonresponse, n (%)

36 (15.0)

49 (6.7)

<0.001

Anti-IL1 antagonist use, n (%)

31 (12.9)

59 (8.1)

0.025

Chronic inflammation, n (%)

37 (15.4)

105 (14.4)

0.6

Median CRP in the last visit, mg/L

11 (6–18)

12 (6–26)

0.26

Amyloidosis, n (%)

14 (5.8)

43 (5.9)

0.97

Damage accrual (ADDI score)

1 (0–1)

1 (0–1)

0.24

Total number of abdominal surgeries till inclusion of study

2 (0–2)

0 (0)

<0.001

Data are presented as median (interquartile range 25–75 percentile), *mean ± standard deviation or number (%). ADDI: autoinflammatory
disease damage index, CRP: C reactive protein, ELE: erysipelas like erythema, IL-1: interleukin-1.

with history of appendectomy had reported more frequent
abdominal operations. Having history of appendectomy
gives some clues about the course of FMF in adulthood.
These patients report more frequent attacks particularly
serositis type episodes despite they use higher doses of
colchicine. Colchicine nonresponse rate is higher and
the need for anti-IL-1 therapies are more pronounced in
appendectomized patients.
FMF patients most frequently present initially with
acute abdominal pain and fever, both of which are also
the common causes of emergency department admissions.
Emergency department is the most common medical care
unit for the first time admissions of FMF patients. As many
patients with acute abdominal pain are discharged from
the emergency department without a definitive diagnosis,
it is not surprising that, due to its rarity, most cases of
FMF remain undiagnosed or are misdiagnosed as acute
appendicitis or other causes of acute surgical abdomen [6].
The diagnosis of FMF requires a high index of suspicion
and careful assessment of clinical history. Family history,
clinical features, in particular history of previous selflimiting acute attacks, together with prodromal symptoms
and triggering factors, are useful to suspect FMF but all
of them are seldom questioned in emergency department
admissions [6].
In our study, it was observed that there is a diagnostic
delay of 10–12 years between the onset of FMF complaints

and the age of diagnosis. Childhood is the peak period
for the diagnosis of acute appendicitis and disease onset
before the age of 10 is more common in appendectomized
patients in our study. It is probable that appendectomy was
performed with a diagnosis of acute appendicitis in the
first or second attack before the FMF diagnosis was made.
Due to difficulties in distinguishing acute appendicitis,
lack of previous diagnosis of FMF and hazy clinical picture
in children might apt to surgeons to operate. Additionally,
longer disease duration might increase emergency
admissions which might increase risk of appendectomy.
Furthermore, in some patients despite an established
diagnosis of FMF, appendectomy is still performed
because of problems in distinguishing typical attack from
appendicitis. According to a study conducted in Israel,
the frequency of appendectomy in FMF patients was
reported to be 16% [16] and in a nationwide multicenter
study evaluating 2838 Turkish FMF patients was 19%
in 2005 [10]. This rate was 24.7% in our study, which
might be lack of knowledge on FMF and pathogenesis of
autoinflammatory diseases among physicians as well as
low public awareness of FMF in the past decades.
Colchicine is the mainstay of FMF treatment. It is
generally safe and well-tolerated. Efficacy of colchicine
has been shown in reducing typical attacks and prevention
of secondary amyloidosis. The recommended dose of
colchicine is 1–2 mg/day for children older than 10 years
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and for adults. However, some patients cannot tolerate
effective doses of colchicine due to its side effects. The
most common side effects of colchicine are diarrhea,
abdominal discomfort and nausea [17,18]. In addition,
despite regular use of highest therapeutic doses, about 10%
of patients do not respond sufficiently to the colchicine
[14]. Overall, approximately 60% of patients respond
well to daily colchicine treatment, while 20%–30% show
partial response and 5%–10% have no response [19].
Similar rate was found in our study with being 8.7%
of patient’s colchicine resistant. However, the rate of
colchicine resistance was twice as more in AP group (15%
vs. 6.7%) despite they had used higher doses of colchicine.
Therefore, history of appendectomy might be instructive
in terms of treatment planning, such as colchicine dosages,
estimation of colchicine response and the need for antiIL-1 treatments.
In our study, ISSF score was 3.13 ± 1.68 in the AP
group with more severe patients in appendectomy
performed group. This is because of occurrence of more
frequent attacks and involvement of more disease sites in
AP group. However, when experienced attacks in the last
year were analyzed which represent adulthood period,
the difference was present for fever and peritonitis/
pleuritis attacks, whereas, the number of musculoskeletal
attacks and erysipelas like erythema in the last year were
similar in both groups. Theoretically, appendectomy by
itself might facilitate occurrence of serositis attacks as
suggested by increased risk of inflammatory diseases
among appendectomized patients in the long term such
as inflammatory bowel disease and sepsis [20,21]. There
was no difference between groups for the development
of amyloidosis or damage accrual. Previous studies have
shown that there is no correlation between frequency of
attacks and the risk of amyloidosis, except for arthritis
which significantly increases the risk of amyloidosis
[22,23]. Frequency of arthritis attacks are the same in both
groups in our study which may explain similar rate of
amyloidosis and ADDI scores.
Our study has some limitations. The most important
limitation is the retrospective design of the study which
impairs evaluation of pre-appendectomy FMF disease
characteristics. The types, numbers and the duration of
attacks were based on the declaration of patients which
depends on patient recall ability. To overcome this, we
included only the number and duration of previous attacks.
The types of attacks were evaluated dichotomously as ever
experienced or not. Another limitation is that we did not
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ask for pathologic examination of surgical specimens;
therefore we cannot decide whether appendectomy or
other operations performed upon true indication or
not. But remarkably high prevalence strongly suggests
unindicated surgeries. Finally, pain severity perceived
by patients might be different and we did not evaluate
pain severity, which is quite subjective with considering
heterogeneity of attacks and lack of a standardized pain
tool in FMF.
In conclusion, appendectomy is common in FMF
patients and careful history taking may reduce unnecessary
operations. Appendectomy patients experience more
frequent attacks, particularly fever, peritonitis/pleuritis
attacks, they display more severe disease and poor response
to colchicine. Hence, history of appendectomy might help
to anticipate disease course and colchicine responses, as
well as to make treatment plans.
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